Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Köllermann J[au]:

Search results

Items: 1 to 50 of 78

1.

Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior Biopsies.

Preisser F, Theissen L, Wenzel M, Humke C, Bodelle B, Köllermann J, Kluth L, Banek S, Becker A, Roos F, Chun FK, Mandel P.

Eur Urol Focus. 2019 Jul 8. pii: S2405-4569(19)30170-1. doi: 10.1016/j.euf.2019.06.015. [Epub ahead of print]

PMID:
31296485
2.

Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center.

Preisser F, Theissen L, Wild P, Bartelt K, Kluth L, Köllermann J, Graefen M, Steuber T, Huland H, Tilki D, Roos F, Becker A, Chun FK, Mandel P.

Eur Urol Focus. 2019 Mar 21. pii: S2405-4569(19)30082-3. doi: 10.1016/j.euf.2019.03.007. [Epub ahead of print]

PMID:
30905598
3.

Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).

Wendler JJ, Pech M, Fischbach F, Jürgens J, Friebe B, Baumunk D, Porsch M, Blaschke S, Schindele D, Siedentopf S, Ricke J, Schostak M, Köllermann J, Liehr UB.

Urology. 2018 Apr;114:224-232. doi: 10.1016/j.urology.2017.12.016. Epub 2018 Jan 2.

PMID:
29305201
4.

Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study.

Wendler JJ, Pech M, Köllermann J, Friebe B, Siedentopf S, Blaschke S, Schindele D, Porsch M, Baumunk D, Jürgens J, Fischbach F, Ricke J, Schostak M, Böhm M, Liehr UB.

Cardiovasc Intervent Radiol. 2018 Mar;41(3):466-476. doi: 10.1007/s00270-017-1795-x. Epub 2017 Sep 19.

PMID:
28929209
5.

[Focal therapy of prostate cancer].

Ganzer R, Franiel T, Köllermann J, Kuru T, Baumunk D, Blana A, Hadaschik B, von Hardenberg J, Henkel T, Köhrmann KU, Liehr UB, Machtens S, Roosen A, Salomon G, Schlemmer HP, Sentker L, Wendler J, Witzsch U, Schostak M.

Urologe A. 2017 Oct;56(10):1335-1346. doi: 10.1007/s00120-017-0488-z. German.

PMID:
28856386
6.

[MRI/TRUS fusion-guided prostate biopsy : Value in the context of focal therapy].

Franz T, von Hardenberg J, Blana A, Cash H, Baumunk D, Salomon G, Hadaschik B, Henkel T, Herrmann J, Kahmann F, Köhrmann KU, Köllermann J, Kruck S, Liehr UB, Machtens S, Peters I, Radtke JP, Roosen A, Schlemmer HP, Sentker L, Wendler JJ, Witzsch U, Stolzenburg JU, Schostak M, Ganzer R.

Urologe A. 2017 Feb;56(2):208-216. doi: 10.1007/s00120-016-0268-1. Review. German.

PMID:
27844131
7.

Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.

Wendler JJ, Ganzer R, Hadaschik B, Blana A, Henkel T, Köhrmann KU, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D, Köllermann J, Schostak M, Liehr UB.

World J Urol. 2017 Jan;35(1):11-20. doi: 10.1007/s00345-016-1838-y. Epub 2016 May 4. Review.

PMID:
27147512
8.

[Focal therapy for small renal masses : Observation, ablation or surgery].

Wendler JJ, Friebe B, Baumunk D, Blana A, Franiel T, Ganzer R, Hadaschik B, Henkel T, Köhrmann KU, Köllermann J, Kuru T, Machtens S, Roosen A, Salomon G, Schlemmer HP, Sentker L, Witzsch U, Liehr UB, Ricke J, Schostak M.

Urologe A. 2016 May;55(5):594-606. doi: 10.1007/s00120-016-0075-8. Review. German.

PMID:
27119957
9.

Follow-up after focal therapy in renal masses: an international multidisciplinary Delphi consensus project.

Zondervan PJ, Wagstaff PG, Desai MM, de Bruin DM, Fraga AF, Hadaschik BA, Köllermann J, Liehr UB, Pahernik SA, Schlemmer HP, Wendler JJ, Algaba F, de la Rosette JJ, Laguna Pes MP.

World J Urol. 2016 Dec;34(12):1657-1665. Epub 2016 Apr 22. Review.

10.

Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison.

Wendler JJ, Fischbach K, Ricke J, Jürgens J, Fischbach F, Köllermann J, Porsch M, Baumunk D, Schostak M, Liehr UB, Pech M.

Pol J Radiol. 2016 Feb 17;81:54-64. doi: 10.12659/PJR.896034. eCollection 2016.

11.

First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial.

Wendler JJ, Ricke J, Pech M, Fischbach F, Jürgens J, Siedentopf S, Roessner A, Porsch M, Baumunk D, Schostak M, Köllermann J, Liehr UB.

Cardiovasc Intervent Radiol. 2016 Feb;39(2):239-50. doi: 10.1007/s00270-015-1200-6. Epub 2015 Sep 4.

PMID:
26341653
12.

[Irreversible electroporation. Current value for focal treatment of prostate cancer].

Wendler JJ, Ganzer R, Hadaschik B, Blana A, Henkel T, Köhrmann KU, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D, Köllermann J, Schostak M, Liehr UB; Working Group for Focal and Microtherapy, Academy of the German Society of Urology.

Urologe A. 2015 Jun;54(6):854-62. doi: 10.1007/s00120-015-3864-6. Review. German.

PMID:
26024649
13.

A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).

Wendler JJ, Porsch M, Nitschke S, Köllermann J, Siedentopf S, Pech M, Fischbach F, Ricke J, Schostak M, Liehr UB.

Contemp Clin Trials. 2015 Jul;43:10-9. doi: 10.1016/j.cct.2015.05.002. Epub 2015 May 9.

PMID:
25962890
14.

[Cancer control in focus insights and future perspectives for the focal treatment of prostate cancer].

Schostak M, Köllermann J, Hadaschik B, Blana A, Ganzer R, Henkel T, Köhrmann KU, Liehr UB, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D.

Aktuelle Urol. 2015 Jan;46(1):39-44. doi: 10.1055/s-0034-1396803. Epub 2015 Feb 6. Review. German.

PMID:
25658230
15.

[Focal therapy for prostate cancer in Germany - 2014 status].

Roosen A, Ganzer R, Hadaschik B, Köllermann J, Blana A, Henkel T, Liehr AB, Baumunk D, Machtens S, Salomon G, Sentker L, Witsch U, Köhrmann KU, Schostak M; Arbeitskreis für Fokale und Mikrotherapie der Akademie der Deutschen Gesellschaft für Urologie e.V.

Urologe A. 2014 Jul;53(7):1040-5. doi: 10.1007/s00120-014-3532-2. Review. German. Erratum in: Urologe A. 2014 Aug;53(8):1214.

PMID:
24941932
16.

Reproducibility of histopathologic tumor grading in penile cancer--results of a European project.

Kakies Ch, Lopez-Beltran A, Comperat E, Erbersdobler A, Grobholz R, Hakenberg OW, Hartmann A, Horn LC, Höhn AK, Köllermann J, Kristiansen G, Montironi R, Scarpelli M, Protzel Ch.

Virchows Arch. 2014 Apr;464(4):453-61. doi: 10.1007/s00428-014-1548-z. Epub 2014 Feb 18.

PMID:
24535700
17.

Significance of Gleason grading of low-grade carcinoma of the prostate with therapeutic option of active surveillance.

Helpap B, Kristiansen G, Köllermann J, Shaikhibrahim Z, Wernert N, Oehler U, Fellbaum C.

Urol Int. 2013;90(1):17-23. doi: 10.1159/000342810. Epub 2012 Oct 24.

PMID:
23095725
18.

[Focal prostate cancer therapy: capabilities, limitations and prospects].

Baumunk D, Blana A, Ganzer R, Henkel T, Köllermann J, Roosen A, Machtens S, Salomon G, Sentker L, Witzsch U, Köhrmann KU, Schostak M; Arbeitsgruppe für Fokale und Mikrotherapie.

Urologe A. 2013 Apr;52(4):549-56. doi: 10.1007/s00120-012-3002-7. Review. German.

PMID:
23073701
19.

Improving the reproducibility of the Gleason scores in small foci of prostate cancer--suggestion of diagnostic criteria for glandular fusion.

Helpap B, Kristiansen G, Beer M, Köllermann J, Oehler U, Pogrebniak A, Fellbaum Ch.

Pathol Oncol Res. 2012 Jul;18(3):615-21. doi: 10.1007/s12253-011-9484-6. Epub 2011 Dec 17.

PMID:
22179685
20.

Combined histoarchitectural and cytological biopsy grading improves grading accuracy in low-grade prostate cancer.

Helpap B, Köllermann J.

Int J Urol. 2012 Feb;19(2):126-33. doi: 10.1111/j.1442-2042.2011.02902.x. Epub 2011 Nov 22.

21.

Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.

Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Fälth M, Köllermann J, Walther R, Schlomm T, Sauter G, Bokemeyer C, Sültmann H, Schuppert A, Brümmendorf TH, Balabanov S.

PLoS One. 2011 Feb 11;6(2):e16833. doi: 10.1371/journal.pone.0016833.

22.

Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage.

Budäus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P, Chun FK, Salomon G, Steuber T, Köllermann J, Sauter G, Ahyai SA, Zacharias M, Fisch M, Schlomm T, Haese A, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz PI.

J Urol. 2010 Oct;184(4):1341-6. doi: 10.1016/j.juro.2010.06.018. Epub 2010 Aug 17.

PMID:
20723925
23.

Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients.

Köllermann J, Albrecht H, Schlomm T, Huland H, Graefen M, Bokemeyer C, Simon R, Sauter G, Wilczak W.

Oncol Lett. 2010 Jul;1(4):729-732. Epub 2010 Jul 1.

24.

Nuclear grading versus Gleason grading in small samples containing prostate cancer: a tissue microarray study.

Wittschieber D, Köllermann J, Schlomm T, Sauter G, Erbersdobler A.

Pathol Oncol Res. 2010 Dec;16(4):479-84. doi: 10.1007/s12253-010-9270-x. Epub 2010 Apr 23.

PMID:
20414754
25.

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.

Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T.

Clin Cancer Res. 2010 Mar 1;16(5):1553-60. doi: 10.1158/1078-0432.CCR-09-2546. Epub 2010 Feb 23.

26.

Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer.

Ahyai SA, Zacharias M, Isbarn H, Steuber T, Eichelberg C, Köllermann J, Fisch M, Karakiewicz PI, Huland H, Graefen M, Chun FK.

BJU Int. 2010 Aug;106(4):478-83. doi: 10.1111/j.1464-410X.2009.09162.x. Epub 2010 Jan 29.

27.

Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.

El Gammal AT, Brüchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T.

Clin Cancer Res. 2010 Jan 1;16(1):56-64. doi: 10.1158/1078-0432.CCR-09-1423. Epub 2009 Dec 22.

28.

Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.

Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M.

BJU Int. 2010 Jul;106(1):37-43. doi: 10.1111/j.1464-410X.2009.09134.x. Epub 2009 Dec 11.

29.

[F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study.

Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF, Haese A, Klutmann S, Köllermann J, Sauter G, Mester J, Mikecz P, Fisch M, Huland H, Graefen M, Salomon G.

Eur J Cancer. 2010 Jan;46(2):449-55. doi: 10.1016/j.ejca.2009.11.008. Epub 2009 Dec 5.

PMID:
19969447
30.

Unilateral prostate cancer cannot be accurately predicted in low-risk patients.

Isbarn H, Karakiewicz PI, Vogel S, Jeldres C, Lughezzani G, Briganti A, Montorsi F, Perrotte P, Ahyai SA, Budäus L, Eichelberg C, Heuer R, Köllermann J, Sauter G, Schlomm T, Steuber T, Haese A, Zacharias M, Fisch M, Heinzer H, Huland H, Chun FK, Graefen M.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):784-7. doi: 10.1016/j.ijrobp.2009.05.068. Epub 2009 Oct 26.

PMID:
19864083
31.

Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer.

Isbarn H, Karakiewicz PI, Ahyai SA, Chun FK, Jeldres C, Haese A, Heinzer H, Zacharias M, Heuer R, Eichelberg C, Steuber T, Budäus L, Köllermann J, Salomon G, Schlomm T, Perrotte P, Fisch M, Huland H, Graefen M.

BJU Int. 2010 Mar;105(6):818-23. doi: 10.1111/j.1464-410X.2009.08841.x. Epub 2009 Sep 14.

32.

Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosis.

Kempkensteffen C, Hinz S, Johannsen M, Krause H, Magheli A, Christoph F, Köllermann J, Schrader M, Schostak M, Miller K, Weikert S.

Tumour Biol. 2009;30(2):73-9. doi: 10.1159/000215826. Epub 2009 Apr 27.

PMID:
19401626
33.

Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure.

Adam C, Salomon G, Walther S, Zaak D, Khoder W, Becker A, Reich O, Blana A, Ganzer R, Denzinger S, Popken G, Sroka R, Knüchel-Clarke R, Köllermann J, Sauter G, Hartmann A, Bertz S, Graefen M, Huland H, Wieland W, Stief CG.

Eur Urol. 2009 Jun;55(6):1281-8. doi: 10.1016/j.eururo.2009.02.027. Epub 2009 Mar 3.

PMID:
19328622
34.

[Trends in prostate biopsy interpretation].

Köllermann J, Sauter G.

Urologe A. 2009 Mar;48(3):305-12; quiz 313-4. doi: 10.1007/s00120-009-1966-8. Review. German.

PMID:
19296072
35.

Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.

Fleischmann A, Schlomm T, Köllermann J, Sekulic N, Huland H, Mirlacher M, Sauter G, Simon R, Erbersdobler A.

Prostate. 2009 Jun 15;69(9):976-81. doi: 10.1002/pros.20948.

PMID:
19274666
36.

[Identification and validation of clinically relevant molecular alterations in prostate cancer].

Schlomm T, Sültmann H, Köllermann J.

Pathologe. 2009 Mar;30(2):111-6. doi: 10.1007/s00292-008-1113-0. German.

PMID:
19139898
37.

Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.

Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A.

Clin Cancer Res. 2008 Dec 1;14(23):7838-42. doi: 10.1158/1078-0432.CCR-08-1432.

38.

Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.

Köllermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, Pantel K.

J Clin Oncol. 2008 Oct 20;26(30):4928-33. doi: 10.1200/JCO.2007.15.0441. Epub 2008 Sep 15.

PMID:
18794550
39.

Seminal vesicle amyloidosis does not provide any protection from invasion by prostate cancer.

Erbersdobler A, Kollermann J, Graefen M, Röcken C, Schlomm T.

BJU Int. 2009 Feb;103(3):324-6. doi: 10.1111/j.1464-410X.2008.08024.x. Epub 2008 Sep 3.

40.

Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series.

Isbarn H, Ahyai SA, Chun FK, Budäus L, Schlomm T, Salomon G, Zacharias M, Erbersdobler A, Köllermann J, Sauter G, Huland H, Graefen M, Steuber T.

Eur Urol. 2009 Feb;55(2):394-401. doi: 10.1016/j.eururo.2008.08.015. Epub 2008 Aug 13.

PMID:
18718699
41.

[Identification and validation of clinically relevant molecular alterations in prostate cancer].

Schlomm T, Sültmann H, Köllermann J.

Urologe A. 2008 Sep;47(9):1193-8. doi: 10.1007/s00120-008-1834-y. German.

PMID:
18712514
42.

Clinical significance of p53 alterations in surgically treated prostate cancers.

Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A.

Mod Pathol. 2008 Nov;21(11):1371-8. doi: 10.1038/modpathol.2008.104. Epub 2008 Jun 13.

43.

Expression of splicing variants of the inhibitor of apoptosis livin in testicular germ cell tumors.

Kempkensteffen C, Hinz S, Krause H, Jager T, Köllermann J, Weikert S, Christoph F, Schostak M, Miller K, Schrader M.

Tumour Biol. 2008;29(2):76-82. doi: 10.1159/000135687. Epub 2008 Jun 2.

PMID:
18515985
44.

Expression and prognostic relevance of annexin A3 in prostate cancer.

Köllermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz A.

Eur Urol. 2008 Dec;54(6):1314-23. doi: 10.1016/j.eururo.2008.01.001. Epub 2008 Jan 16.

PMID:
18222597
45.

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6579-84.

46.

Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.

Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.

Eur Urol. 2008 Apr;53(4):750-7. Epub 2007 Oct 17.

PMID:
17964070
47.

Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.

Schostak M, Krause H, Miller K, Schrader M, Kempkensteffen C, Kollermann J.

BJU Int. 2007 Jun;99(6):1409-14. Epub 2007 Apr 8.

48.

Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance.

Kempkensteffen C, Hinz S, Christoph F, Köllermann J, Krause H, Schrader M, Schostak M, Miller K, Weikert S.

Int J Cancer. 2007 Mar 1;120(5):1081-6.

49.

Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer.

Christoph F, Kempkensteffen C, Weikert S, Köllermann J, Krause H, Miller K, Schostak M, Schrader M.

Br J Cancer. 2006 Dec 18;95(12):1701-7. Epub 2006 Nov 28.

50.

Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.

Schostak M, Miller K, Krause H, Schrader M, Kempkensteffen C, Kollermann J.

Cancer Detect Prev. 2006;30(5):449-54. Epub 2006 Oct 25.

PMID:
17067752

Supplemental Content

Loading ...
Support Center